Erickson Michael G

Erickson Michael G, Executive Vice President at IDEXX Laboratories (IDXX), has been a consistent seller of company stock over the past year, with no open-market purchases on record. Across 42 total Form 4 filings, all involving IDXX, his transactions amount to roughly $3.69 million in sales, while his acquisition activity consists entirely of option exercises (code M) and equity grants (code A) — compensation events rather than discretionary buys. The most recent cluster of activity, dated February 17–19, 2026, shows a clear pattern: six open-market sales totaling approximately $3.09 million, paired with option exercises valued at about $1.11 million. The largest single sale, at $1.69 million, occurred on February 17, alongside additional sales of $806,618, $433,443, and smaller tranches of $284,434, $127,549, and $25,195. The February 2026 sales follow a similar disposition in August 2025, when Erickson sold roughly $320,930 worth of IDXX shares in three transactions. Notably, the February 14, 2026 filing also includes a tax-withholding event (code F) valued at $612,987, which is an automatic share surrender rather than a discretionary trade. The option exercises on February 14 and 19, several valued at zero, are mechanical conversions that typically precede or accompany sales. The overall trajectory is unambiguous: Erickson has monetized equity compensation aggressively in recent months, with all discretionary activity tilted toward selling. His last open-market purchase, if any, is not reflected in the recent data, underscoring a sustained disposition bias across the trailing twelve months.